| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | 76.60% | 70.71% | 60.36% | 43.52% | 19.99% | 11.62% |
| Operating Margin | -35.84% | -26.34% | -56.23% | -129.21% | -233.64% | -241.26% |
| EBITDA Margin | -33.41% | -23.79% | -51.65% | -121.28% | -216.05% | -215.01% |
| Net Margin | -28.96% | -19.62% | -54.57% | -136.22% | -215.50% | 187.87% |
| Current Ratio | 10.95 | 11.36 | 8.06 | 7.81 | 15.92 | 7.03 |
| Quick Ratio | 9.75 | 10.50 | 7.22 | 6.95 | 15.19 | 6.31 |
| Debt / Equity | — | — | 0.00 | 0.45 | 0.29 | -0.06 |
| ROE | -14.13% | -9.76% | -30.31% | -74.25% | -35.22% | -6.40% |
| ROA | -12.49% | -8.62% | -26.63% | -44.46% | -25.26% | 27.39% |
| Asset Turnover | 0.43 | 0.44 | 0.49 | 0.33 | 0.12 | 0.15 |
| Book Value / Share | 6.75 | 7.24 | 4.65 | 3.25 | 10.15 | -77.83 |
RxSight Inc. is a healthcare company specializing in the development and commercialization of innovative ophthalmic implantable devices. Its primary product line includes light adjustable lenses, which allow patients to adjust and customize their vision post-cataract surgery, enhancing visual outcomes. This ability to fine-tune vision is achieved using proprietary technology that utilizes ultraviolet light to adjust the lens power after surgical implantation and healing. RxSight Inc. plays a significant role in the ophthalmology sector, particularly in refractive cataract surgery, offering an advanced solution that addresses limitations of traditional intraocular lenses. With a focus on improving patient satisfaction and enhancing the precision of vision correction, RxSight Inc. is pivotal in advancing eye care solutions and is a key player in medical innovation within the healthcare market landscape.